News Conference News AHA 2021 Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time: EMPULSE Shelley Wood November 14, 2021
News Conference News TCT 2021 GUIDE-HF Hints That Hemodynamic-Guided Management Works in HFpEF Michael O'Riordan November 06, 2021
News Daily News As Amyloidosis Field Explodes, Physicians Need to Spot and Treat Todd Neale October 20, 2021
News Features Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle Shelley Wood October 08, 2021
News Features When the Time Comes to Stop Oral Anticoagulation: Options and Obstacles Todd Neale September 28, 2021
News Conference News HFSA 2021 PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF Todd Neale September 13, 2021
News Conference News ESC 2021 In HFrEF, AI Shows Promise For Predicting Beta Blocker Response Yael L. Maxwell September 03, 2021
News Conference News ESC 2021 EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF Todd Neale August 27, 2021
News Conference News HRS 2021 Heart Failure Patients With AF Benefit From Early Rhythm Control Shelley Wood July 30, 2021
News Conference News TVT 2021 Optimizing Medical Therapy Before Clip Repair for MR? ‘This Is Hard’ Todd Neale July 27, 2021
News Daily News Studies Explore Post-MI Use of Beta-blockers, Mineralocorticoid Receptor Antagonists Todd Neale July 09, 2021
News Conference News ACC 2021 Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF Michael O'Riordan May 25, 2021
News Conference News ACC 2021 ‘Enormous’ QoL Improvements With Mavacamten in HCM Shelley Wood May 15, 2021
News Daily News Hints of Benefit With Levosimendan in Pulmonary Hypertension Due to HFpEF Michael O'Riordan April 15, 2021
News Daily News Continue ACE Inhibitors/ARBs in COVID-19, New Study Confirms Michael O'Riordan April 02, 2021